This Medical Technology Stock Claws Back To A Buy Zone

Medical technology stock Halozyme Therapeutics (HALO) is back above a prior base buy point and hit a record high on Tuesday. Halozyme specializes in a patented drug delivery technology and recently teamed up with biotech name Incyte (INCY). Analysts expect Halozyme's profit to grow 91% in 2026. These highlights and others make the biotech name Wednesday's IBD 50 Growth Stocks To…